RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oral drug targets Tough-to-Treat leukemia
Disease control TerminatedThis early-stage trial tests an experimental oral drug called GB3226 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug works by blocking two pathways that help leukemia cells grow. The study aims to find a safe dose and check f…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: Galecto Biotech AB • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental CAR-T therapy targets tough leukemia
Disease control TerminatedThis early-stage trial is testing a new treatment called CT0991, which uses specially engineered immune cells (CAR-T cells) to fight acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The study involves 24 adults aged 18-75 and aims to check saf…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: He Huang • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC